Waist-to-Hip Ratio in PCOS: A Better Marker Than BMI

Why does BMI perform so poorly for body composition in PCOS?

BMI cannot tell trunk fat from hip fat, and that blind spot matters more in PCOS than in most conditions. A 2021 systematic review of 39 imaging studies found women with PCOS carry significantly more trunk and android fat than BMI-matched women without it — meaning two people can share an identical BMI while one carries her extra weight around the middle and the other around the hips and thighs, with meaningfully different metabolic risk attached to each pattern. BMI is a ratio of weight to height; it has no way to register that difference at all. That’s the specific gap that waist-to-hip ratio (WHR) — waist circumference divided by hip circumference — is built to catch, because it directly compares central mass against peripheral mass rather than just totalling weight.

What waist-to-hip ratio actually counts as high risk?

A waist-to-hip ratio of 0.85 or higher in women is the World Health Organization’s threshold for substantially increased risk of metabolic complications, alongside 0.90 for men. That figure comes from the WHO’s own expert consultation on the measure, and it sits alongside two other widely used systems that define central obesity slightly differently. The International Diabetes Federation’s 2006 consensus uses waist circumference rather than the ratio, and sets its qualifying threshold for men at over 94 cm for people of European descent but over 90 cm for South Asian, Chinese and Japanese men — a 4 cm difference built directly into the consensus table. The IDF’s threshold for women, 80 cm, is applied the same way across those same groups, which is itself lower than the US National Cholesterol Education Program’s single, non-ethnicity-specific cutoff of 88 cm for women.

Does ethnicity really change the threshold, or is that a footnote?

It’s a documented, guideline-level difference, not a footnote — most clearly in the men’s row of the table above, where the IDF sets a 4 cm lower bar for South Asian, Chinese and Japanese men than for men of European descent. The IDF’s 2006 consensus made that adjustment specifically because a growing body of research found that people in those groups develop insulin resistance and metabolic complications at a smaller waist size than people of European descent do — the same absolute measurement carries more risk in some populations than others. A 2009 joint statement from the IDF and five other major cardiometabolic organisations reinforced the point further, concluding that no single global waist-circumference cutoff currently fits every population well and recommending regional or national thresholds be used in the meantime rather than one universal number. If you’re comparing your own measurement against a published cutoff, which specific cutoff applies is itself a real clinical question — one worth raising with a clinician who knows your background, not something to resolve by picking whichever number reads most reassuring.

How does waist-to-hip ratio actually connect to insulin resistance in PCOS?

Waist circumference — the numerator in the ratio — correlates with insulin resistance more tightly than almost any other single measurement used in PCOS research. A 2006 study of 40 women with PCOS found a correlation of r=0.68 between visceral fat mass and insulin resistance, and concluded that waist circumference — not weight, and not BMI — was the best simple proxy available for insulin resistance in the group studied.

The study below uses the label PMOS: in May 2026, a global consensus of more than 50 medical organisations renamed PCOS polyendocrine metabolic ovarian syndrome — same condition, same mechanism, and this article uses PCOS because that’s still what most readers search.

A far larger, more recent dataset confirms the same threshold is still in active clinical use: a 2026 study of 580 women newly diagnosed with PMOS used a waist-to-hip ratio above 0.85 as one criterion for classifying clinical obesity, the same figure the WHO consultation set two decades earlier. The same study went further and tested whether combining waist-to-hip ratio with a triglyceride-glucose marker into a single composite score predicted insulin resistance better than either measure alone — it did not clearly outperform simpler options. Across seven different insulin-resistance indices tested, including that composite, none identified every clinically obese woman in the cohort who actually had insulin resistance.

Can you actually measure visceral fat at home?

Not directly — visceral fat itself requires a CT, MRI or DXA scan to measure, and none of those happen at home. What waist circumference and waist-to-hip ratio give you instead is a validated proxy: a home measurement standing in for a metabolic risk that tracks with visceral fat and its downstream effect on insulin resistance — the same r=0.68 relationship described above. To measure correctly, stand upright, breathe out normally, and measure waist circumference at the midpoint between the bottom of your lowest rib and the top of your hip bone, using a tape that sits snug but doesn’t compress the skin. Measure hip circumference around the widest part of your buttocks. Divide waist by hip to get the ratio. Take both measurements first thing in the morning if you can, since waist size can shift 1–2 cm over the course of a day with food and fluid intake.

Is waist-to-hip ratio the best marker, or has something else overtaken it?

Waist-to-height ratio (WHtR) — waist circumference divided by height — is increasingly favoured over waist-to-hip ratio in newer research, and the honest comparison should say so rather than oversell WHR as settled science. A study of 66 women with PCOS in Kolkata, India found WHtR outperformed BMI at detecting both PCOS and insulin resistance — but with two different cutoffs, not one: 0.560 for detecting PCOS itself, and a higher 0.620 for detecting insulin resistance specifically within that PCOS group. A WHtR between those two numbers means PCOS-level risk without yet crossing the higher, insulin-resistance-specific threshold — a distinction worth holding onto rather than reading any number above 0.560 as “insulin resistance.” Both cutoffs are genuinely useful, but come from one small, single-city sample not yet replicated widely enough to treat as fixed. BMI remains the weakest of the three at detecting central adiposity, waist-to-hip ratio is a validated step up with real ethnicity-adjusted thresholds behind it, and waist-to-height ratio may edge it out further — “may,” not a settled replacement.

Where this will not be the right marker for you

None of the ratios above are diagnostic alone, and a ratio under the threshold does not rule out insulin resistance — lean PCOS can carry real insulin resistance at a body size that produces an unremarkable ratio. Waist-to-hip ratio also loses accuracy during and after pregnancy, and with any hip or spine condition that changes normal body shape. And if a clinician can order an SHBG or HOMA-IR test, that result is a more precise marker than any tape-measure ratio — this is a screening tool for when a lab test isn’t available yet, not a replacement for one that is.

Your next step

Measure your waist and hip circumference once this week using the technique above, calculate the ratio, and write both raw numbers down — not just the ratio — so you can re-check them in three months. This sits alongside the site’s broader take on why PCOS shifts fat toward the abdomen and how insulin resistance drives that pattern; central fat also shows up in fatty liver risk through the same mechanism, and if you’re weighing medication options for the underlying insulin resistance, GLP-1 access and cost covers what that decision actually involves. This is one entry in the weight-loss guide, which treats every number on this page as a metabolic signal to track, not a target to chase.